Biotech company Pharmaxis Ltd
(ASX:PXS) has suffered another setback in its bid to market its cystic fibrosis in the United States.
The US Food and Drug Administration have rejected the drug, Bronchitol, instead recommending an additional clinical trial.
The regulatory body claimed the trial had not proved favourable for cystic fibrosis patients, over the age of 6.
Pharmaxis last reported a net loss of $21 million. for the period to December 31.
